ClinicalTrials.gg
Active, not recruitingNCT05639010Updated Mar 23, 2026

Effects of Hemodialysis Plus Hemoperfusion in Maintenance Hemodialysis Patients: A Clinical Study

An interventional study of regular hemodialysis and hemoperfusion combined with hemodialysis in End Stage Renal Disease, sponsored by Changhai Hospital. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Changhai Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
410
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 114 studies in Kidney Failure, Chronic with a site in China — 28 open to participants now, 36 under way, 1 of them phase 3. Kidney Failure, Chronic · China.

Planned enrollment
17th of 83
410 · median 150
Started
2023
with 3 others
No phase
40 of 114
9 open now
Primary completion
2026-12
later than 20 of 35 live
Registered
73rd of 114
by date

Among the 114 studies in Kidney Failure, Chronic with a site in China, this one is the 17th largest by planned enrollment of the 83 interventional ones that give a count, is one of 4 that started in 2023, is one of 40 with no phase, reaches primary completion later than 20 of the 35 other live ones, and was the 73rd registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

28 of the 114 studies in Kidney Failure, Chronic with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Kidney Failure, Chronic with a site in China, or all of them as a file.
02

Study summary

This multi-center, open-label, randomized, parallel controlled trial aims to investigate the efficacy of hemoperfusion (HP) in combination with hemodialysis (HD) by assessing blood β2-microglobulin (β2-MG), parathyroid hormone (PTH) and C reactive protein (CRP) clearance in maintenance hemodialysis patients.

Read the detailed description

In this HD/HP vs HD trial, the investigators plan to enroll 410 maintenance hemodialysis patients. Twelve medical centers in the Shanghai metropolitan area have expressed interest in participating. Participants will be randomized into 2 groups after a 1-month washout period. The control group (205 patients) will be treated with hemodialysis or hemofiltration with a frequency of 3 times/week; the experimental group (205 patients) will be treated with Jafron KHA80 hemoperfusion apparatus in addition to hemodialysis or hemofiltration with a frequency of 1 time/week. Follow-up data before the last dialysis at 4, 12, 24, 36 and 52 weeks of treatment were collected from both groups, including the following: routine physical examination, laboratory tests (blood routine, blood biochemistry, β2-MG, PTH, CRP, liver/kidney function, coagulation system tests, etc.), chest X-ray, electrocardiogram and cardiac ultrasound. Dialysis adequacy as defined by standard Kt/V will be calculated. Comorbidities, combined medications and adverse events will also be captured. The primary outcomes will include change in blood β2-MG, PTH and CRP values. Secondary outcomes will include change values for serum protein-bound toxins (e.g., p-Cresol sulfate, indophenol sulphate), improvement in patient quality of life (Kidney Disease Quality of Life Short Form), sleep disturbance (Pittsburgh Sleep Quality Index) and pruritus (Duo's pruritus score).

03

Conditions studied

  • End Stage Renal Disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-80 years, regardless of gender
  2. Stable maintenance hemodialysis for ≥ 3 months with relatively fixed dialysis pattern
  3. Hemodialysis treatment 3 times per week, total treatment duration ≥ 10 hours per week, vascular access unlimited
  4. Blood β2-MG > 30 mg/L and/or 300 pg/ml \< immunoreactive parathyroid hormone (iPTH) \< 800 pg/ml and/or CRP ≥ 16.2 pg/ml
  5. Kt/V ≥ 1.2 eight weeks prior to enrollment
  6. Signed form

Exclusion criteria

Exclusion Criteria:

  1. Known allergic reaction, or intolerance to the material of the dialyzer or perfusion apparatus
  2. Test indicators meeting one or more of the following: white blood cell \<4 x 10\^9/L, count \<60 x 10\^9/L, serum albumin \<30 g/L
  3. Blood flow \<200 ml/min
  4. Regular hemoperfusion treatment for more than 3 months and at least once every 2 weeks
  5. Active bleeding or chronic gastrointestinal bleeding, or other severe bleeding tendencies or coagulation disorders
  6. History of unstable angina pectoris, myocardial infarction, severe arrhythmia, pericarditis, myocarditis, cardiac surgery or peripheral vascular surgery in the last 8 weeks
  7. Cerebral hemorrhage in the last 12 weeks
  8. Severe heart failure ( class IV)
  9. Acute infection, acute or critical illnesses such as severe cardiac, pulmonary, hepatic or neurological disease and
  10. Pregnancy or breastfeeding
  11. Participation in a clinical trial or ongoing clinical trial within 3 months
  12. Expected survival of less than 1 year
  13. Not considered suitable for participation in this trial by the investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
410 participants (estimated)

Study arms

  • Active comparator
    regular hemodialysis

    Routine blood purification therapy (including hemodialysis, hemofiltration) 3 times a week

    Device: regular hemodialysis

  • Experimental
    hemoperfusion combined with hemodialysis

    Routine blood purification therapy 3 times a week + Combination of hemodialysis and hemoperfusion treatment once a week

    Device: regular hemodialysis · Device: hemoperfusion combined with hemodialysis

Interventions

  • Deviceregular hemodialysis

    Routine blood purification therapy (including hemodialysis, hemofiltration) 3 times a week

  • Devicehemoperfusion combined with hemodialysis

    Hemoperfusion combined with hemodialysis treatment will perform once a week. The hemoperfusion apparatus will use type KHA80 hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)

06

What researchers measure

Primary outcomes

  1. Changes in blood β2-microglobulin (β2-MG) values

    Compared the difference between standardized therapy and hemoperfusion combined with hemodialysis treatment on the clearance of blood β2-MG in maintenance hemodialysis patients

    Time frame: From date of enrollment until the end of study, assessed up to 52 weeks

  2. Changes in blood Parathyroid Hormone (PTH) values

    Compared the difference between standardized therapy and hemoperfusion combined with hemodialysis treatment on the clearance of blood PTH in maintenance hemodialysis patients

    Time frame: From date of enrollment until the end of study, assessed up to 52 weeks

  3. Changes in blood C Reactive Protein (CRP) values

    Compared the difference between standardized therapy and hemoperfusion combined with hemodialysis treatment on the clearance of blood CRP in maintenance hemodialysis patients

    Time frame: From date of enrollment until the end of study, assessed up to 52 weeks

Secondary outcomes

  1. Change in serum protein-bound toxin (e.g., p-Cresol sulfate, indophenol sulphate) values

    Compared the difference between standardized therapy and hemoperfusion combined with hemodialysis treatment on the clearance of serum protein-bound toxin (e.g., p-Cresol sulfate, indophenol sulphate) in maintenance hemodialysis patients

    Time frame: From date of enrollment until the end of study, assessed up to 52 weeks

  2. Improvement in patients' quality of life

    Assessment of quality of life using the Kidney Disease Quality of Life Short Form (KDQOL-SF) questionnaire

    Time frame: From date of enrollment until the end of study, assessed up to 52 weeks

  3. Improvement in patients' sleep disturbance

    Assessment of sleep disturbance using the Pittsburgh Sleep Quality Index (PSQI)

    Time frame: From date of enrollment until the end of study, assessed up to 52 weeks

  4. Improvement in patients' pruritus

    Assessment of pruritus using the Duo's pruritus score

    Time frame: From date of enrollment until the end of study, assessed up to 52 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Huang W, Zhang L, Wu H, Chen W, Guo Z. Effects of combined haemodialysis-haemoadsorption therapy in maintenance haemodialysis patients: study protocol for a multicentre, open-label, randomised, parallel controlled trial. BMJ Open. 2025 Nov 12;15(11):e107017. doi: 10.1136/bmjopen-2025-107017. PubMed 41224301 ↗

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in the publication article, after deidentification (text, tables, figures, and appendices), will be shared.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: The available data period begins 3 months and ends 5 years following the article's publication.

Access criteria: Investigators who provide a methodologically sound proposal for scientific research with non-commercial purposes will be able to access the IPD and supporting information. Deidentified participant data that underlie the results reported in the publication article will be shared, which can be available from Professor Zhiyong Guo (contacting email: drguozhiyong@163.com, ORCID: Shenneike66). Proposals should be directed to drguozhiyong@163.com. To gain access, data requestors will need to sign a data access agreement.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Dec 2026, 47 months after the start.

Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 47 months is above that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2022
First posted
Dec 6, 2022
StartActual
Jan 1, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05639010
Lead sponsor
Changhai Hospital
Responsible party
Sponsor
First posted
Dec 6, 2022
Start date
Jan 1, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 23, 2026

Study contacts

Zhiyong Guo, professor
study director · Changhai Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion